Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06276361
Other study ID # ROV-QUAR-2023-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 26, 2023
Est. completion date May 2026

Study information

Verified date May 2023
Source Rovi Pharmaceuticals Laboratories
Contact Clinical Operations Laboratorios farmacéuticos ROVI
Phone +34913756230
Email departamento.medico@rovi.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths in participants with schizophrenia.


Description:

The study will assess the PK, safety and tolerability of QUAR when administered as a single IM injection, in patients with schizophrenia. The study will be conducted with 3 different dose strengths and up to two formulations. After eligibility confirmation, an oral treatment period follow by a washout period will be performed before QUAR IM administration. The different cohorts will be administered with one of the following dosages of Risperidone QUAR: Cohort 1/2: Formulation 1 or 2. Dose level 1 (Gluteal); Cohort 1a/2a: Formulation 1 or 2. Dose level 2 (Gluteal); Cohort 1b/2b: Formulation 1 or 2. Dose level 3 (Gluteal); Cohort 1c/2c: Formulation 1 or 2. Dose level 3 (Deltoid); The progression to the next cohorts will take place after a clinical safety assessment. Several blood samples for plasma pharmacokinetic (PK) assessments will be obtained pre-dose and post-dose. Safety assessments will be conducted at each pre-specified time points. After assessment of Cohort 1 (formulation 1, Dose Level 1, -gluteus-) progression to the next cohort with same formulation and escalating dose will take place (Cohort 1a -gluteus-). After assessment of Cohort 1a, progression and randomization (gluteus/deltoid) to the next cohorts with same formulation and escalating dose will take place (Cohort 1b -gluteus- and Cohort 1c -deltoid-). In this scenario, none of the Cohorts 2 will be conducted. If the assessment for Cohort 1 is not adequate, none of the subsequent Cohorts 1 (a/b/c) will be conducted and progression to the next cohort (Cohort 2) with different formulation and same level of dose as Cohort 1 will take place (Cohort 2: Formulation 2, Dose Level 1 -gluteus-). After assessment of Cohort 2, progression to the next cohort with same formulation and escalating dose will take place (Cohort 2a -gluteus-). After assessment of Cohort 2a, progression and randomization (gluteus/deltoid) to the next cohorts with same formulation and escalating dose will take place (Cohort 2b -gluteus- and Cohort 2c -deltoid-).


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date May 2026
Est. primary completion date May 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Capable of providing informed consent. - Male or female aged = 18 years to < 65 years with BMI =17.0 to =35.0 kg/m2 - Current diagnosis of schizophrenia, according to the Diagnostic and DSM-5 criteria. - Medically stable over the last month, and psychiatrically stable without significant symptom exacerbation over the last three months based on the investigator's judgment - currently taking oral risperidone as maintenance therapy - Score of = 4 (moderately ill at most) on the Clinical Global Impression - Severity of Illness (CGI-S) - If a sexually active female of childbearing potential, using a medically accepted method of birth control. Exclusion Criteria: - Presence of an uncontrolled, unstable, clinically significant medical condition that in the opinion of the investigator could interfere with the interpretation of safety and PK evaluations - If female, a positive serum pregnancy test, or planning to become pregnant between signing informed consent and 1 month after the last dose of study drug or is breastfeeding a child. - History of neuroleptic malignant syndrome and current or past history of clinically significant tardive dyskinesia. - The participant has a primary diagnosis other than schizophrenia diagnosis that is primarily responsible for current symptoms and functional impairment - Positive test result for drugs of abuse or alcohol unless the positive finding can be accounted for by documented prescription use. - In the investigator's opinion, at imminent risk of committing self-harm or harm to others. - Unwilling to discontinue any of the prohibited medications prior to the baseline visit or unable to safely washout such medication without significant destabilization or increased risk of self-harm (suicide). - Receipt study drug in another investigational study in the last 90 days. - Current participation in any other clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oral risperidone; QUAR F1/2, Dose 1 - Gluteal
Dose level 1
Oral risperidone; QUAR F1/2, Dose 2 - Gluteal
Dose level 2
Oral risperidone; QUAR F1/2, Dose 3 - Gluteal
Dose level 3
Oral risperidone; QUAR F1/2, Dose 3 - Deltoids
Dose level 3

Locations

Country Name City State
Jordan Investigational Site Amman

Sponsors (1)

Lead Sponsor Collaborator
Rovi Pharmaceuticals Laboratories

Country where clinical trial is conducted

Jordan, 

Outcome

Type Measure Description Time frame Safety issue
Primary ?z Terminal elimination rate constant Following Oral and QUAR administration until day 17 or 196 respectively
Primary t1/2 Terminal elimination half-life Following Oral and QUAR administration until day 17 or 196 respectively
Primary Tmax Time to peak concentration Following Oral and QUAR administration until day 17 or 196 respectively
Primary Cmax Peak plasma concentration Following Oral and QUAR administration until day 17 or 196 respectively
Primary Cmin Minimum plasma concentration Following Oral and QUAR administration until day 17 or 196 respectively
Primary Clast Last observed plasma concentration Following Oral and QUAR administration until day 17 or 196 respectively
Primary AUC0-t Area under the curve Following Oral and QUAR administration until day 17 or 196 respectively
Primary AUCinf Area under the curve Following QUAR administration until day 196
Primary AUCextrap Area under the curve Following QUAR administration until day 196
Primary Vd/F Apparent volume of distribution Following Oral and QUAR administration until day 17 or 196 respectively
Primary Cl/F Apparent total body clearance Following Oral and QUAR administration until day 17 or 196 respectively
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A